FY2025 · ended Sep 30, 2025 · Revenue $321.33B, +9.3% YoY · Filed Nov 25, 2025
Cencora, Inc. (COR) files with the SEC under industry code 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries. In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $321.3 billion and net income of $1.6 billion. Free cash flow was $3.2 billion. As of Jun 30, 2026 it held $2.8 billion in cash and investments and $11.7 billion in total debt.
Revenue (TTM)
$332.77B
+5.1% vs year-ago TTM
Net income (TTM)
$2.62B
+38.3% vs year-ago TTM
Operating cash flow (TTM)
$4.82B
+176.7% vs year-ago TTM
Free cash flow (TTM)
$4.06B
+255.7% vs year-ago TTM
EPS (TTM)
$13.46
+39.0% vs year-ago TTM
Dividend per share (TTM)
$2.35
+8.8% vs year-ago TTM
Shares outstanding
193.99M
+0.4% vs prior year
Net cash
$-8.91B
as of Jun 30, 2026
Operating margin
0.9%
FY 2026
Company profile
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
- Listed as
- COR (NYSE)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Conshohocken, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1140859
- Former names
- AMERISOURCEBERGEN CORP (until Aug 15, 2023); AMERISOURCE BERGEN CORP (until Oct 9, 2001)
Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- Mckesson Corp MCK
- Cardinal Health Inc CAH
- Herbalife Ltd. HLF
- Nu Skin Enterprises, Inc. NUS
- EnerSyn Global Inc. ESYN
- Cosmos Health Inc. COSM
- DataMeds AI, Inc. MEDS
- Cellyan Biotechnology Co., Ltd HKPD
All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $321.3B | $294.0B | $262.2B | $238.6B | $214.0B |
| Operating income | $2.6B | $2.2B | $2.3B | $2.4B | $2.4B |
| Net income | $1.6B | $1.5B | $1.7B | $1.7B | $1.5B |
| Diluted EPS | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 |
| Operating cash flow | $3.9B | $3.5B | $3.9B | $2.7B | $2.7B |
| Free cash flow | $3.2B | $3.0B | $3.5B | $2.2B | $2.2B |
| Total assets | $76.6B | $67.1B | $62.6B | $56.6B | $57.3B |
| Stockholders' equity | $1.5B | $645.9M | $522.0M | -$211.6M | $223.4M |
| Cash and investments | $4.4B | $3.1B | $2.6B | $3.4B | $2.5B |
| Total debt | $9.3B | $5.6B | $5.9B | $6.7B | $7.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 21, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 25, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 14, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
All 1000 Cencora, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.